Tickers

1. Composite Trajectory Verdict

All three financial statements carry roughly equal weight for a diversified medical technology company with significant acquisition activity, debt financing, and recurring legal and remediation contingencies.

Composite Trajectory: Mixed

Revenue and operating income have grown consistently over the three-year annual period (FY2023–FY2025), and gross margin has expanded. However, net income and diluted EPS from continuing operations dipped slightly in FY2025 versus FY2024, operating cash flow declined year-over-year in FY2025, and the balance sheet shows a sharp reduction in cash, elevated debt levels, and declining shareholders’ equity. The improving operating trends are offset by deteriorating cash generation and balance sheet leverage.

2. Red Flags

• Net income decline despite revenue growth: Net income from continuing operations fell to $1,678M in FY2025 from $1,705M in FY2024 while revenue rose 8.2% (10-K 2025-09-30, Consolidated Statements of Operations).
• Operating cash flow reversal: Cash from continuing operations dropped to $3,430M in FY2025 from $3,844M in FY2024, driven by higher inventory, prepaid expenses, and a $175M SEC settlement payment (10-K 2025-09-30, Consolidated Statements of Cash Flows; MD&A Cash Flows from Continuing Operating Activities).
• Cash balance halved: Cash, equivalents, and short-term investments fell to $851M at September 30, 2025 from $1,856M a year earlier (10-K 2025-09-30, Consolidated Statements of Cash Flows).
• Recurring high specified items: After-tax impact of specified items rose to $2,477M in FY2025 from $2,119M in FY2024 and $2,050M in FY2023, including $1,898M of purchase accounting adjustments and $548M of product/litigation/other items (10-K 2025-09-30, MD&A Specified Items).
• Elevated leverage: Total debt stood at $19.2B at FY2025 (42.6% of total capital), down only modestly from $20.1B (42.9%) at FY2024, and up from $15.9B (37.2%) at FY2023 (10-K 2025-09-30, MD&A Debt-Related Activities).
• Large legal and remediation accruals: Accruals for product liability and other legal matters totaled approximately $1.8B at FY2025 and $1.9B at FY2024 (10-K 2025-09-30, Note 6 Litigation Accruals).
• Product remediation charges: $98M recorded in FY2025 cost of products sold to adjust future remediation cost estimates (10-K 2025-09-30, MD&A Specified Items footnote (e)).
• Accumulated foreign currency translation losses: AOCI includes a -$1,353M cumulative translation adjustment at FY2025, worsening from -$1,244M at FY2024 (10-K 2025-09-30, Consolidated Balance Sheets / Note 4).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Revenue increased each year: $19,372M (FY2023) → $20,178M (FY2024) → $21,840M (FY2025) (10-K 2025-09-30, Consolidated Statements of Operations). Gross margin expanded from 42.2% (FY2023) to 45.2% (FY2024) to 45.4% (FY2025) (10-K 2025-09-30, MD&A Gross Profit Margin). Operating income rose steadily: $2,111M → $2,397M → $2,579M (10-K 2025-09-30, Consolidated Statements of Operations). However, net income from continuing operations plateaued: $1,530M → $1,705M → $1,678M, and diluted EPS from continuing operations slipped to $5.82 from $5.86 (10-K 2025-09-30, Consolidated Statements of Operations). The divergence reflects higher net interest expense ($575M vs $364M vs $403M), rising specified items, and a volatile effective tax rate (10.8% vs 15.0% vs 7.9%) (10-K 2025-09-30, MD&A Net Interest Expense; MD&A Income Taxes; MD&A Specified Items).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Operating cash flow grew from $2,990M (FY2023) to $3,844M (FY2024) but fell to $3,430M (FY2025) (10-K 2025-09-30, Consolidated Statements of Cash Flows). Capital expenditures remained relatively stable ($874M → $725M → $760M) (10-K 2025-09-30, Consolidated Statements of Cash Flows). Free cash flow (operating minus capex) peaked at $3,119M in FY2024 before declining to $2,670M in FY2025. Investing cash flow swung to -$5,514M in FY2024 due to the Advanced Patient Monitoring acquisition, then normalized to -$818M in FY2025 (10-K 2025-09-30, Consolidated Statements of Cash Flows). Financing activities shifted from a $2,087M inflow in FY2024 (debt issuance) to a -$3,617M outflow in FY2025 (debt repayment, $1B share repurchase, $1.196B dividends) (10-K 2025-09-30, Consolidated Statements of Cash Flows). The net result was a $1,005M decrease in cash in FY2025, leaving a closing balance of $851M (10-K 2025-09-30, Consolidated Statements of Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Total assets contracted from $57,286M (FY2024) to $55,325M (FY2025) (10-K 2025-09-30, Consolidated Balance Sheets). Cash and short-term investments dropped 54% to $851M (10-K 2025-09-30, Consolidated Statements of Cash Flows). Total debt remained high at $19,181M (FY2025) versus $20,110M (FY2024) and $15,879M (FY2023), with debt-to-capital at 42.6% (FY2025) vs 42.9% (FY2024) vs 37.2% (FY2023) (10-K 2025-09-30, MD&A Debt-Related Activities). Shareholders’ equity declined to $25,390M from $25,890M (10-K 2025-09-30, Consolidated Balance Sheets). Inventories rose slightly to $3,894M from $3,843M (10-K 2025-09-30, Consolidated Balance Sheets). Goodwill increased to $26,612M from $26,465M, reflecting the Advanced Patient Monitoring acquisition (10-K 2025-09-30, Consolidated Balance Sheets; Note 13). The combination of reduced liquidity, persistent high leverage, and declining equity indicates balance sheet deterioration.

6. Data Gaps

• Quarterly revenue, earnings, and cash flow trends (Q4 FY2025, Q1–Q3 FY2026) – the provided 10-Q filings were not included in the document set.
• FY2023 balance sheet details (total assets, debt breakdown, equity) – only FY2024 and FY2025 balance sheets are presented.
• Segment-level cash flow contributions – not disclosed in the filings.
• Free cash flow conversion rate – not directly reported; requires derivation from operating cash flow and capex.
• Detailed debt maturity profile beyond the listed note tranches – not provided in the excerpts.
• Post-combination pro forma financials for the Biosciences/Diagnostic Solutions separation – not available.